# Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

> **NCT00866138** · PHASE2 · COMPLETED · sponsor: **AB Science** · enrollment: 24 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** masitinib (AB1010)

## Key facts

- **NCT ID:** NCT00866138
- **Lead sponsor:** AB Science
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00866138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00866138, "Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00866138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*